Rotenone decreases intracellular aldehyde dehydrogenase activity: Implications for the pathogenesis of Parkinson's disease

Journal of Neurochemistry

Volumn 133, Issue 1, 2015, Pages 14-25

  Goldstein, David S ^a   Sullivan, Patti ^a   Cooney, Adele ^a   Jinsmaa, Yunden ^a   Kopin, Irwin J ^a   Sharabi, Yehonatan ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

3 4 dihydroxyphenyl acetaldehyde; aldehyde dehydrogenase; Parkinson's disease; rotenone; vesicular monoamine transporter

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALDEHYDE DEHYDROGENASE; CATECHOL; DOPAMINE DERIVATIVE; HYDROXYTYROSOL; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROTENONE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2; DOPAMINE; UNCOUPLING PROTEIN;

ANIMAL CELL; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DEAMINATION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; INCUBATION TIME; LIQUID CHROMATOGRAPHY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN TUMOR; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; GLIOBLASTOMA; GLIOMA; METABOLISM; PC12 CELL LINE;

ANIMALIA; RODENTIA;

3,4-DIHYDROXYPHENYLACETIC ACID; ALDEHYDE DEHYDROGENASE; ANIMALS; BRAIN NEOPLASMS; DOPAMINE; ELECTRON TRANSPORT COMPLEX I; GLIOBLASTOMA; GLIOMA; HUMANS; NAD; PARKINSON DISEASE, SECONDARY; PC12 CELLS; RATS; ROTENONE; UNCOUPLING AGENTS;

EID: 84924543628     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13042     Document Type: Article

References (37)

1. Anderson D. G., Mariappan S. V., Buettner G. R., and, Doorn J. A., (2011) Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. J. Biol. Chem. 286, 26978-26986.
2. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V., and, Greenamyre J. T., (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
3. Burke W. J., Li S. W., Williams E. A., Nonneman R., and, Zahm D. S., (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res. 989, 205-213.
4. Burke W. J., Kumar V. B., Pandey N., et al,. (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115, 193-203.
5. Casida J. E., Ford B., Jinsmaa Y., Sullivan P., Cooney A., and, Goldstein D. S., (2014) Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease. Chem. Res. Toxicol. 27, 1359-1361.
6. Chiu C. C., Yeh T. H., Lai S. C., et al,. (2015) Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism. Exp. Neurol. 263, 244-253.
7. Dukes A. A., Korwek K. M., and, Hastings T. G., (2005) The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells. Antioxid. Redox Signal. 7, 630-638.
8. Eiden L. E., and, Weihe E., (2011) VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann. N.Y Acad. Sci. 1216, 86-98.
9. Ferrante R. J., Schulz J. B., Kowall N. W., and, Beal M. F., (1997) Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 753, 157-162.
10. Fitzmaurice A. G., Rhodes S. L., Lulla A., et al,. (2013) Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc. Natl Acad. Sci. USA 110, 636-641.
11. Fitzmaurice A. G., Rhodes S. L., Cockburn M., Ritz B., and, Bronstein J. M., (2014) Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease. Neurology 82, 419-426.
12. Goldstein D. S., Sullivan P., Cooney A., Jinsmaa Y., Sullivan R., Gross D. J., Holmes C., Kopin I. J., and, Sharabi Y., (2012) Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 Cells: relevance to the pathogenesis of Parkinson disease. J. Neurochem. 123, 932-943.
13. Goldstein D. S., Sullivan P., Holmes C., Miller G. W., Alter S., Strong R., Mash D. C., Kopin I. J., and, Sharabi Y., (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J. Neurochem. 126, 591-603.
14. Goldstein D. S., Kopin I. J., and, Sharabi Y., (2014a) Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol. Ther. 144, 268-282.
15. Goldstein D. S., Sullivan P., Holmes C., Miller G. W., Sharabi Y., and, Kopin I. J., (2014b) A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease. J. Neurochem. 131, 219-228.
16. Halliday G. M., Li Y. W., Blumbergs P. C., Joh T. H., Cotton R. G., Howe P. R., Blessing W. W., and, Geffen L. B., (1990) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27, 373-385.
17. Hoglinger G. U., Feger J., Prigent A., Michel P. P., Parain K., Champy P., Ruberg M., Oertel W. H., and, Hirsch E. C., (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84, 491-502.
18. Holmes C., Eisenhofer G., and, Goldstein D. S., (1994) Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Biomed. Appl. 653, 131-138.
19. Jinsmaa Y., Sullivan P., Gross D., Cooney A., Sharabi Y., and, Goldstein D. S., (2014) Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. Neurosci. Lett. 569, 27-32.
20. Kazantsev A. G., and, Kolchinsky A. M., (2008) Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch. Neurol. 65, 1577-1581.
21. Kish S. J., Shannak K., and, Hornykiewicz O., (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876-880.
22. Lamensdorf I., Eisenhofer G., Harvey-White J., Hayakawa Y., Kirk K., and, Kopin I. J., (2000a) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J. Neurosci. Res. 60, 552-558.
23. Lamensdorf I., Eisenhofer G., Harvey-White J., Nechustan A., Kirk K., and, Kopin I. J., (2000b) 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res. 868, 191-201.
24. Lees A. J., Selikhova M., Andrade L. A., and, Duyckaerts C., (2008) The black stuff and Konstantin Nikolaevich Tretiakoff. Mov. Disord. 23, 777-783.
25. Leiphon L. J., and, Picklo M. J., Sr, (2007) Inhibition of aldehyde detoxification in CNS mitochondria by fungicides. Neurotoxicology 28, 143-149.
26. Liu H. Q., Zhu X. Z., and, Weng E. Q., (2005) Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells. Acta Pharmacol. Sin. 26, 17-26.
27. Meyer M. J., Mosely D. E., Amarnath V., and, Picklo M. J., Sr, (2004) Metabolism of 4-hydroxy-trans-2-nonenal by central nervous system mitochondria is dependent on age and NAD+ availability. Chem. Res. Toxicol. 17, 1272-1279.
28. Panneton W. M., Kumar V. B., Gan Q., Burke W. J., and, Galvin J. E., (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS ONE 5, e15251.
29. Sai Y., Wu Q., Le W., Ye F., Li Y., and, Dong Z., (2008) Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism. Toxicol. In Vitro 22, 1461-1468.
30. Sherer T. B., Kim J. H., Betarbet R., and, Greenamyre J. T., (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179, 9-16.
31. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R., and, Goedert M., (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
32. Tanner C. M., Kamel F., Ross G. W., et al,. (2011) Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 119, 866-872.
33. Tao-Cheng J. H., and, Eiden L. E., (1998) The vesicular monoamine transporter VMAT2 and vesicular acetylcholine transporter VAChT are sorted to separate vesicle populations in PC12 cells. Adv. Pharmacol. 42, 250-253.
34. Taylor T. N., Alter S. P., Wang M., Goldstein D. S., and, Miller G. W., (2014) Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology, 76 Pt A, 97-105.
35. Watabe M., and, Nakaki T., (2007) Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells. J. Pharmacol. Exp. Ther. 323, 499-507.
36. Watabe M., and, Nakaki T., (2008) Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol. Pharmacol. 74, 933-940.
37. Wu Y. N., and, Johnson S. W., (2011) Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-D-aspartate currents in rat substantia nigra dopamine neurons. Neuroscience 195, 138-144.